Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3020% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker Adjusted R&D Expense (% of Net Sales) by Year
Adjusted R&D Expense (% of Net Sales) (%)
Stryker Adjusted R&D Expense (% of Net Sales): 6.2% in FY2025, down 0.1 pts from a year earlier.
Latest, FY2025
6.2%
Period ended Dec 31, 2025
Change on a year earlier
-0.1 pts
6.3% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
Reported in Stryker Form 8-K Non-GAAP Reconciliations.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adjusted R&D Expense (% of Net Sales) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.2% | -0.1 pts | 0000310764-26-000006|sykex991earningsq42025.htm ↗ |
| FY2024 | Dec 31, 2024 | 6.3% | 0.0 pts | 0000310764-25-000005|sykex991earningsq42024.htm ↗ |
| FY2023 | Dec 31, 2023 | 6.3% | -0.4 pts | 0000310764-24-000005|sykex991earningsq42023.htm ↗ |
| FY2022 | Dec 31, 2022 | 6.7% | +0.1 pts | 0000310764-23-000005|sykex991earningsq42022.htm ↗ |
| FY2021 | Dec 31, 2021 | 6.6% | +0.3 pts | 0000310764-22-000008|sykex991earningsq42021.htm ↗ |
| FY2020 | Dec 31, 2020 | 6.3% | – | 0000310764-21-000005|sykex991earningsq42020.htm ↗ |
Cite this data
StockData. (2026). Stryker Adjusted R&D Expense (% of Net Sales) (%), annual FY2020–FY2025 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/core-ng-rd-pct
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.